Core Viewpoint - The company plans to sign a technical cooperation development contract with Nanjing University to jointly develop anti-thrombotic small nucleic acid drugs, with a total contract amount of 15 million RMB (including tax) [1] Company Summary - The company will pay the cooperation fees to Nanjing University in installments according to the project development plan outlined in the contract [1] - Upon successful development and market launch of the target drug, the company will pay Nanjing University a percentage of the annual revenue generated by the drug for a period of 10 years [1] - The collaboration aims to leverage Nanjing University's strong research capabilities in nucleic acid drugs and the company's industrialization and clinical development capabilities to advance the research and commercialization of innovative drugs [1] Industry Summary - The domestic small nucleic acid drug market is primarily dominated by imported drugs, indicating significant growth potential in the domestic market compared to the global market [1] - With increasing policy support and capital investment, the development of small nucleic acid drugs in China is progressing rapidly, and the domestic market is expected to experience rapid growth [1] - The company's early entry into the small nucleic acid drug field is aimed at seizing market opportunities, supported by a deep understanding of local market demands and the strategic alignment with its cardiovascular treatment focus [1]

Core Viewpoint - The company plans to collaborate with Nanjing University for the joint development of "anti-thrombotic small nucleic acid drugs," with a transaction amount of 15 million yuan [1] Group 1 - The collaboration aims to leverage academic research for drug development [1] - The transaction amount indicates a significant investment in innovative pharmaceutical research [1]

Core Viewpoint - Company plans to sign a technology cooperation development contract with Nanjing University to jointly develop anti-thrombotic small nucleic acid drugs, with a total contract amount of 15 million RMB (including tax) [1] Company Summary - The company will pay cooperation fees to Nanjing University in installments according to the project development plan outlined in the contract [1] - Upon successful development and market launch of the target drug, the company will pay Nanjing University a percentage of the annual revenue generated by the drug for a period of 10 years [1] - The collaboration aims to leverage Nanjing University's strong research capabilities in nucleic acid drugs and the company's industrialization and clinical development capabilities to advance the research and commercialization of innovative drugs [1] Industry Summary - The domestic small nucleic acid drug market is primarily dominated by imported drugs, indicating significant growth potential in the domestic market compared to the global market [1] - With increasing policy support and capital investment, the development of small nucleic acid drugs in China is progressing rapidly, positioning the company to seize market opportunities [1] - The target drug aligns with the company's strategic planning in the cardiovascular treatment field, enhancing its core competitiveness in research and injecting new momentum into the innovation drug product pipeline [1]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has received the approval notice for the supplementary application of Tadalafil tablets, which is expected to enhance the company's product line and market competitiveness [1][4]. Group 1: Drug Information - Tadalafil tablets are primarily used for the treatment of erectile dysfunction (2.5mg and 5mg specifications) and for erectile dysfunction combined with benign prostatic hyperplasia (only 5mg specification) [1]. - As of the announcement date, the domestic sales revenue of Tadalafil tablets in sample hospitals for 2024 is approximately 142.73 million yuan [1]. Group 2: Research and Development - The company has invested approximately 11.95 million yuan in the research and development of Tadalafil tablets (2.5mg, 5mg, 10mg, 20mg) as of the announcement date [2]. - In 2025, the company has obtained 11 product varieties, 13 production approvals, and 2 clinical approvals [3]. Group 3: Impact on the Company - The approval of the Tadalafil tablets is expected to enrich the company's product line and enhance its market competitiveness, although it is not anticipated to have a significant impact on the company's recent operating performance [4].

Group 1 - Yongtai Technology's wholly-owned subsidiary has received approval for trial production of a lithium battery additive project with an annual capacity of 5,000 tons, set to begin trial production [1] - Mengke Pharmaceutical has decided to terminate its plan to issue shares to a specific entity due to ongoing disagreements among major shareholders, which could impact the company's stable operations [1] - Anhui Construction's subsidiary has been approved to register and issue debt financing tools totaling 15 billion yuan, including 5 billion yuan in short-term financing notes and 10 billion yuan in medium-term notes [2] Group 2 - Koli'er plans to repurchase shares worth between 10 million and 20 million yuan, with a maximum repurchase price of 20.94 yuan per share, to implement an employee stock ownership plan [2] - Xinhua Pharmaceutical has received approval for the production of fumaric acid volnoral raw materials, which are used to treat gastroesophageal reflux disease [3] - Lianhuan Pharmaceutical has received approval for additional specifications of tadalafil tablets, expanding its product offerings for treating erectile dysfunction and benign prostatic hyperplasia [5] Group 3 - Greenland Holdings reported an increase of 1,834 lawsuits with a total amount of 6.587 billion yuan from October 21 to November 13, 2025 [7] - Lianke Technology plans to invest up to 600 million yuan of idle funds in low-risk financial products [8] - Yinglian Co. signed a strategic procurement contract for 5,000 million square meters of composite aluminum foil with a leading new energy technology company [10] Group 4 - China Eastern Airlines reported a 10.58% year-on-year increase in passenger turnover for October, with a capacity increase of 6.84% [12] - China National Airlines reported an 8.7% year-on-year increase in passenger turnover for October, with domestic and international capacity also showing growth [15] - Oupai Home plans to use 320 million yuan of idle funds to purchase structured deposits with expected annual yields between 0.65% and 2.50% [16] Group 5 - Tianwei Food has submitted H-share issuance application materials to the Hong Kong Stock Exchange, which have been accepted by the China Securities Regulatory Commission [18] - Guizhou Aviation plans to establish a subsidiary focused on the research, production, and market expansion of intelligent automotive components, with initial operating funds of 40 million yuan [20] - Daimai Co. plans to invest 100 million yuan to establish a wholly-owned subsidiary in Shanghai focused on robotics technology [22] Group 6 - Founder Securities has received approval to issue company bonds totaling up to 30 billion yuan [24] - Hengrui Medicine has received clinical trial approvals for multiple drugs, indicating ongoing research and development efforts [26] - Zhaojing Pharmaceutical's product ZG006 has received orphan drug designation from the FDA, providing various benefits for its development in the U.S. market [39]

证券代码：600513 证券简称：联环药业 公告编号：2025—086 江苏联环药业股份有限公司 关于公司获得《药品补充申请批准通知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于近日收到国家药品监 督管理局核准签发的关于他达拉非片（以下简称"本品"或"该药品"）《药 品补充申请批准通知书》。现将相关情况公告如下： 1 药品名称 他达拉非片 剂型 片剂 注册分类 化学药品 规格 2.5mg 5mg 包装规格 每盒 1 板，每板 14 片 每盒 1 板，每板 12 片 原药品批准文号 国药准字 H20233231 受理号 CYHB2400818 CYHB2400823 通知书编号 2025B05371 2025B05372 申请内容 药学研究信息；其他：根据《已上市化学药品药学变更研究技术指导 原则（试行）》，本品在 20mg 的规格基础上增加 2.5mg、5mg 的规格。 上市许可持有人 名称：江苏联环药业股份有限公司 地址：江苏省扬州市扬州生物健康产业园健康一路 9 ...

Core Viewpoint - The approval of additional specifications for tadalafil tablets by the National Medical Products Administration is expected to enhance the product line of the company, although it is not anticipated to have a significant impact on recent performance due to uncertainties in drug sales [1] Group 1: Product Approval - The company has received approval for tadalafil tablets in 2.5mg and 5mg specifications [1] - Tadalafil is used for the treatment of erectile dysfunction [1] Group 2: Financial Impact - The estimated sales revenue for tadalafil in domestic sample hospitals is approximately 142.72 million yuan for 2024 [1] - The company has invested around 11.95 million yuan in the research and development of this drug [1] Group 3: Future Prospects - In 2025, the company is expected to obtain 11 varieties, 13 production licenses, and 2 clinical licenses [1] - The approval is seen as a way to enrich the product line, but the sales of the drug remain uncertain [1]

Core Viewpoint - The company, Lianhuan Pharmaceutical, has received approval from the National Medical Products Administration for the supplemental application of Tadalafil tablets, allowing for the introduction of new specifications [1] Group 1: Product Approval - The approval includes the addition of 2.5mg and 5mg specifications for Tadalafil tablets [1] - Tadalafil is primarily used for the treatment of erectile dysfunction in both 2.5mg and 5mg specifications, and for the treatment of erectile dysfunction combined with benign prostatic hyperplasia only in the 5mg specification [1]

（文章来源：证券日报） 证券日报网讯 11月13日晚间，联环药业发布公告称，公司于近日收到公司间接股东扬州产业投资发展 集团有限责任公司（简称"产发集团"）的通知，扬州市人民政府国有资产监督管理委员会已将其所持产 发集团6.45%的股权无偿划转至江苏省财政厅。截至本公告披露日，公司间接股东产发集团相关工商变 更登记手续已办理完成。 ...

证券代码：600513 证券简称：联环药业 公告编号：2025-085 江苏联环药业股份有限公司 特此公告。 关于公司间接股东股权结构变动完成的公告 江苏联环药业股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 11 月 14 日 江苏联环药业股份有限公司（以下简称"联环药业"或"公司"）于近日收 到公司间接股东扬州产业投资发展集团有限责任公司（以下简称"产发集团"） 的通知，扬州市人民政府国有资产监督管理委员会已将其所持产发集团 6.45%的 股权无偿划转至江苏省财政厅。具体内容详见公司于 2025 年 11 月 8 日在上海证 券交易所网站（http://www.sse.com.cn）和指定信息披露媒体披露的《联环药 业关于控股股东股权结构变动的提示性公告》（公告编号：2025-083）。 截至本公告披露日，公司间接股东产发集团相关工商变更登记手续已办理完 成。 敬请广大投资者理性投资，注意投资风险。 ...